Novocure Receives IDE Approval to Initiate METIS Trial

Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the United States Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the METIS trial. METIS is a …

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the PANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields (TTFields) plus chemotherapy in 40 patients …

Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer

Trial tests safety and potential synergy between a taxane and TTFields in the treatment of recurrent ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the INNOVATE trial, a phase 2 pilot trial testing Tumor Treating Fields (TTFields) therapy in combination with weekly paclitaxel for the …

Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients

Median overall survival exceeded 15 months in patients with locally advanced pancreatic cancer treated with TTFields therapy combined with gemcitabine ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that a new subgroup analysis of its ongoing phase 2 pilot PANOVA clinical trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting …

Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016

Results demonstrate that TTFields enhance immunogenic cell death in non-small cell lung cancer cells in vivo ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will present new data at the American Association of Immunologists’ Annual Meeting on May 13-17, 2016, in Seattle showing that Tumor Treating Fields (TTFields) in combination with PD-1 inhibitors led to additive efficacy …

Novocure Enters into Employment Agreement with William Doyle

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today announced that it has entered into an employment agreement with William Doyle, current Chairman and Director, to formally establish his role as Executive Chairman. “Given our dynamic growth, we believe there is significant value in expanding …

Novocure Reports First Quarter 2016 Financial Results and Provides Company Update

Three months ended March 31, ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported financial results for the first quarter ended March 31, 2016, highlighting strong growth in prescriptions, active patients and reported revenues.             First quarter 2016 highlights …

Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma

New programs respond to unmet needs described by the GBM community ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today it will deliver new programs to support the glioblastoma (GBM) community during Brain Tumor Awareness Month. Last year, Novocure held events to listen to the needs of the GBM community, learn how to better support patients …

Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer

Website and traveling exhibit to support glioblastoma community ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure™ (NASDAQ: NVCR) announced today the availability of a new online resource to raise awareness of glioblastoma (GBM) and share stories of inspiration with the GBM community. An interactive exhibit featuring patients, caregivers, doctors, nurses and advocates will also be displayed within the coming …

Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune

More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Blue Cross Blue Shield of Michigan now covers Optune for members who have newly diagnosed or recurrent glioblastoma (GBM). Blue Cross Blue Shield of Michigan administers medical …